2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Cell Expansion, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Immunology, Immunodeficiency, Infectious Diseases, Viral, Bacterial, Fungal, Other Pathogens, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Measurable Residual Disease, ALL, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

6284 Specialized outpatient infrastructure and higher-dose dexamethasone prophylaxis support safe outpatient CAR-T therapy: A single-center experience

Sally Jones, MD, Aditi Saha, MD2, Naga Swetha S Samji, MD3, Rick Foust, MD4, Elizabeth Sewell, BSN5, Lucy Bailey, MSN6, Ibrahim Muhsen, MD7, Firas Baidoun, MD8, Lauren Shea, MD9, Amitkumar Mehta, MD10
1 University of Alabama at Birmingham, Birmingham, Alabama, United States
2 University of Alabama at Birmingham, Birmingham, Alabama, United States
3 University of Alabama at Birmingham, Birmingham, Alabama, United States
4 University of Alabama at Birmingham, Birmingham, Alabama, United States
5 University of Alabama at Birmingham, Birmingham, Alabama, United States
6 University of Alabama at Birmingham, Birmingham, Alabama, United States
7 University of Alabama at Birmingham, Birmingham, Alabama, United States
8 University of Alabama at Birmingham, Birmingham, Alabama, United States
9 University of Alabama at Birmingham, Birmingham, Alabama, United States
10 University of Alabama at Birmingham, Birmingham, Alabama, United States

Introduction

Historically, chimeric antigen receptor T-cell (CAR T) therapy required inpatient admission for monitoring for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) driving substantial resource utilization and financial burden. Emerging data support structured ambulatory ecosystem can prevent hospitalization while permitting safe and efficacious application of CAR T therapy. We report our experience with outpatient CAR T therapy in patients (pts) with lymphoma at University of Alabama at Birmingham (UAB).

Methods

Between 11/2024 and 05/2026, 38 adult pts with R/R B-cell lymphoma received outpatient CAR T therapy at UAB. Pts resided within 1 hour of UAB with caregiver, self-monitored, had 24/7 access to a clinic, and underwent daily outpatient evaluation through day 10 after CAR T infusion. CRS/ICANS protocols were established for early intervention with tocilizumab and dexamethasone (dex). Most pts received prophylactic dex (20 mg daily for 3 days). Primary endpoints were rate of hospitalization within day 30 of CAR T infusion. Secondary endpoint included safety (incidence/severity of CRS, ICANS, infection, cytopenias) and efficacy (overall response rate [ORR] and complete response [CR] rate).

Results

Median age at CAR T infusion was 71.5 years (range, 40–90); 35 pts (92.1%) were Caucasian, with equal sex distribution. Diffuse large B-cell lymphoma predominated (n=32; 84.2%). Bulky disease was present in 9 pts (23.7%) and 22 (57.9%) had extranodal involvement. Pts received a median of 1 prior line of therapy (range, 1-3) and 18 (47.4%) received bridging therapy. Lisocabtagene maraleucel was administered to 35 pts (92.1%) and axicabtagene ciloleucel to 3 (7.9%). Prophylactic dex was administered to 29 pts (76.3%). Pts completed a median of 11 outpatient visits during the first 2 weeks after infusion (range, 3–13).

Twenty-nine pts (76.3%) avoided hospitalization within 30 days of CAR T infusion. Nine pts (23.7%) required hospitalization within 30 days (≤ day 3, n=1; days 4–7, n=3; days 8–30, n=5). Hospitalization within the first 7 days were exclusively due to CRS/ICANS; among days 8–30 admissions, 3 were due to CRS/ICANS, and 2 due to infection. Among the 9 patients who did not receive prophylactic dex, 2 were hospitalized: 1 for ICANS and 2 for sepsis. Median duration of hospitalization was 7 days (range, 1–36). Two pts (5.3%) required ICU escalation, 1 for severe ICANS and 1 for septic shock.

Any-grade CRS occurred in 19 pts (50.0%), all grade 1-2, with a median onset day 4 (range,1-6) and median duration 2 days (range, 1–5). ICANS occurred in 8 pts (21.1%), including grade ≥3 in 5 pts (13.2%) with a median onset day 5 (range, 3-20) and median duration of 6 days (range, 1–18). Outpatient tocilizumab and dex were administered in 19 (50.0%) and 17 (44.7%) pts, respectively allowing majority (13; 34.2%) of CRS and low grade ICANS events to be treated outpatient successfully.

Infections occurred in 8 pts (21.1%) (bacterial [15.8%], viral [5.3%], and fungal [2.6%]) with 6 (15.8%) being within 30 days. All but 1 pt developed cytopenia: severe neutropenia (ANC ≤500/µL) in 26 (68.4%), prolonged neutropenia (>30 days) in 10 (26.3%), febrile neutropenia in 11 (28.9%), anemia (Hb ≤ 8 g/dL) in 5 (13.2%), severe thrombocytopenia (≤ 50,000/µL) in 12 (31.6%), and thrombocytopenia persisting beyond day 30 in 13 (34.2%).

The ORR and CR rates were 91.9% and 86.5%, respectively. At data cutoff, 6 pts (15.8%) had experienced disease progression and 5 (13.2%) had died. One death occurred within 7 days of CAR T infusion, 2 (5.3%) occurred between 30-80 days, and 2 (5.3%) occurred beyond 180 days. Causes of death included disease progression (n=2; 5.3%), immune effector cell-mediated toxicity including ICANS and HLH-like syndrome (n=2; 5.3%), and septic shock (n=1; 2.6%).

Conclusions

Our experience showed specialized outpatient CAR T ecosystem incorporating intensive follow-up, 24/7 access to expert evaluation, predefined toxicity management pathways, self-monitoring education and prophylactic high dose dexamethasone allowed more than two third patients to avoid hospitalization within 30 days with minimal requirement of ICU escalation. CRS was largely low grade, manageable in the ambulatory setting and efficacy was preserved. These data support broader implementation of structured outpatient CAR T programs for prospective validation including formal assessment resource utilization and cost.

Sally Jones, MD: No relevant conflicts of interest to declare.